EP
IPSC icon

Eversept Partners’s Century Therapeutics IPSC Stock Holding History

Eversept Partners’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100,901
Closed -$2.96M – 114
2021
Q2 		$2.96M Buy
+100,901
New +$2.56M 0.2% 60

Other funds holding IPSC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Eversept Partners's IPSC Position: Q3 2021 in Review

Eversept Partners sold out of Century Therapeutics (IPSC) in Q3 2021, closing a stake of 100,901 shares — an estimated $2.96M sold.

Eversept Partners first reported a position in IPSC in Q2 2021 and held it in 1 quarter. The position peaked at $2.96M in Q2 2021. 49 funds tracked by Wall St. Rank hold IPSC as of Q3 2021.

  • Eversept Partners reported no remaining Century Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Eversept Partners sold 100,901 Century Therapeutics shares in Q3 2021, an estimated $2.96M.
  • Eversept Partners first reported a position in Century Therapeutics in Q2 2021 and held it in 1 quarter.
  • Eversept Partners's Century Therapeutics position peaked at $2.96M in Q2 2021.
  • 49 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2021.

Based on Eversept Partners's 13F filing for Q3 2021, filed 15 Nov 2021.